DarioHealth Presents New Data at American Diabetes Association's 78th Scientific Sessions on June 25, 2018
17,156 T2D Users of DarioHealth Experience a Shift from Greater than 180 mg/dL to Normal Glucose Levels with Sustainable Results
Jun 25, 2018
CAESAREA, Israel, June 25, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported new data at the American Diabetes Association's (ADA) 78th Scientific Sessions which takes place in Orlando, Florida from June 22-26, 2018. On Monday June 25, 2018 from 12:00 pm – 1:00pm ET, DarioHealth's Head of Commercialization for North America, JC Muyl, is delivering three poster presentations.
The poster presentations and a summary of the data reported are the following:
- Type 2 Diabetes (T2D) Users of [Dario's] Digital Diabetes Management System Experience a Shift from Greater than 180 mg/dL to Normal Glucose Levels with Sustainable Results
- Data from 17,156 type 2 diabetes (T2D) users were analyzed
- 19% reduction in average ratio of high glucose events
- 11% increase in ratio of normal range readings
- Most significant shift occurred after one month of usage with stability over the following months throughout the full year
- After a year, users show higher improvement rate
- Decrease in High Readings and Severe Hyperglycemic Events for People with T2D over the Full Year of 2017 in Users Monitoring with a Digital Diabetes Management System
- Data from 225 T2D active users
- 20% reduction in occurrences of high hyperglycemic events
- 58% decrease in occurrences of severe hyperglycemia events
- Continuous Reduction of Blood Glucose Average during One Year of Glucose Monitoring Using a Digital Monitoring System in a High-Risk Population
- Data from 238 highly engaged T2D users whose average blood glucose level was above 180mg/dL in the first 30 days of measurements (225±45 mg/dL) showed continuous reduction in glucose level average vs. baseline
- 7%, 11% and 14% reduction at 3, 6, and 12 months respectively in blood glucose average level
- 76% of the population improved their average blood glucose level over a year, showing an average decrease of 10%, 16% and 24% in their blood glucose average following 3, 6 and 12 months, respectively
"Data presented in these posters offer evidence that a new paradigm of treatment, which leverages digital technology, empowers people living with diabetes and creates improved outcomes. We are pleased to present these data to healthcare professionals at the ADA's 78th Scientific Sessions and we believe this exchange will lead to broader adoption of the Dario solution," commented Erez Raphael, Chairman and CEO of DarioHealth.
João Mendes-Roter, DarioHealth's Vice President of Marketing added, "These results are a sign of DarioHealth's commitment to offer the best tools and support to our users, allowing them to live better with their diabetes. Real-time, personalized data in the hands of users offers actionable information that supports people to optimize their own diabetes management. This is Dario's mission."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company states that data presented offer evidence that a new paradigm of treatment, which leverages digital technology, empowers people living with diabetes and creates improved outcomes, or that it believes this exchange will lead to broader adoption of the Dario solution, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact: Shmuel Herschberg, Marketing Director, email@example.com, +1-914-775-5548
DarioHealth Public Relations Contact: Terese Kelly, Rosica PR, firstname.lastname@example.org, +1-201-843-5600
DarioHealth Investor Relations Contact: Westwicke Partners, Dario@Westwicke.com, +1-443-213-0500
SOURCE DarioHealth Corp.